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Background: CD4+ T-cell epitopes play a crucial role in eliciting vigorous protective immune responses during
peptide (epitope)-based vaccination. The prediction of these epitopes focuses on the peptide binding process by
MHC class II proteins. The ability to account for MHC class II polymorphism is critical for epitope-based vaccine
design tools, as different allelic variants can have different peptide repertoires. In addition, the specificity of CD4+
T-cells is often directed to a very limited set of immunodominant peptides in pathogen proteins. The ability to
predict what epitopes are most likely to dominate an immune response remains a challenge.
Results: We developed the computational tool Predivac to predict CD4+ T-cell epitopes. Predivac can make
predictions for 95% of all MHC class II protein variants (allotypes), a substantial advance over other available
methods. Predivac bases its prediction on the concept of specificity-determining residues. The performance of the
method was assessed both for high-affinity HLA class II peptide binding and CD4+ T-cell epitope prediction. In
terms of epitope prediction, Predivac outperformed three available pan-specific approaches (delivering the highest
specificity). A central finding was the high accuracy delivered by the method in the identification of
immunodominant and promiscuous CD4+ T-cell epitopes, which play an essential role in epitope-based vaccine
design.
Conclusions: The comprehensive HLA class II allele coverage along with the high specificity in identifying
immunodominant CD4+ T-cell epitopes makes Predivac a valuable tool to aid epitope-based vaccine design in the
context of a genetically heterogeneous human population.The tool is available at: http://predivac.biosci.uq.edu.au/.
Keywords: CD4+ T-cell epitope prediction, Epitope-based vaccination, Immunodominance, MHC (HLA) class II
proteins, MHC (HLA) class II polymorphism, Pan-specific, Peptide binding prediction, Peptide vaccination, Specificity-
determining residuesBackground
Epitope-based vaccines (EVs) make use of short, antigen-
derived peptides (corresponding to epitopes) that are
administered to trigger a protective humoral (B-cell epi-
topes) and/or cellular (T-cell epitopes) immune response.
T-cell epitopes are presented to T-cells in association with
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reproduction in any medium, provided the orcytotoxic T-cells recognize intracellular peptides displayed
by MHC class I molecules (CD8+ T-cell epitopes), T
helper cells recognize peptides that are taken up from the
extracellular space and displayed by MHC class II mole-
cules (CD4+ T-cell epitopes). The peptide:MHC complex
(pMHC) interacts with the T-cell receptor, leading to its
activation and subsequent induction of a cellular immune
response. EVs offer several potential benefits over trad-
itional vaccines, including the precise control over the
immune response activation, the ability to focus on the
most relevant antigen regions (conserved and/or highly
immunogenic), as well as production and biosafety
advantages due to their chemically simple and well-
characterized composition. CD4+ T-cell epitopes play al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these cells is essential for the generation of vigorous
humoral and cytotoxic CD8+ T-cell responses [2]. Because
experimental screening of large sets of peptides is time-
consuming and costly, in silico methods that facilitate
CD4+ T-cell epitope mapping on protein antigens are
paramount for EV development.
Human MHC class II (HLA class II) proteins are made
up of two transmembrane chains: α-chain (34 kDa) and
β-chain (29 kDa), which together shape the peptide-
binding groove. This region defines five pockets that
mostly interact with individual residues of the peptide [3].
The HLA genes are the most polymorphic in the human
genome. Currently, the IMGT/HLA database [4] lists
1679 HLA class II alleles associated with three classical
loci (1267 DR, 223 DQ and 189 DP alleles), corresponding
to 931 distinct HLA class II DR protein variants (allotypes;
as of September 2012), and this number continues to grow
at a rate of 200 alleles per year [5]. This huge diversity
poses serious problems for vaccine design, as different
alleles are expressed at dramatically different frequencies
in different ethnicities. Individuals display different sets of
alleles that likely respond to a different set of peptides
from a given pathogen.
The MHC class II binding groove is open at both ends,
allowing peptides (~9-22 residues long) to project out of
the groove, causing ambiguity in their positional align-
ment and making the alignment a fundamental step in
predicting binding. Two classes of methods for CD4+ T-
cell epitope prediction have emerged. The first category
(data-driven methods) relies on peptide sequence compar-
isons to identify binding motifs, and includes the pioneer
method SYFPEITHI [6] and matrix-based approaches
such as position-specific binding profiles (e.g. Rankpep
[7], ARB [8] and SMM-align [9]). TEPITOPE [10] and
TEPITOPEpan [11] are based on the so-called “pocket
profiles” and MultiRTA [12] is based on thermodynamic
principles. Another group of data-driven approaches
involves machine learning, which has been proposed to
capture subtle MHC class II-binding patterns (e.g. NN-
align [13], NetMHCIIPan-2.0 [14] and MHCIIMulti [15]).
The second category involves structure-based methods.
These methods perform molecular modeling calculations
on pMHCs in order to estimate the binding energies, thus
offering independence from experimental binding data. A
recent analysis showed them to be better than random, but
inferior to state-of-the-art data-driven approaches [16].
The few methods able to cope with the extent of HLA
class II polymorphism are collectively referred to as
pan-specific approaches [17]. Although these methods
(NetMHCIIPan-2.0, TEPITOPEpan, MultiRTA) are poten-
tially suitable for EV design, they do not fully account for
the entire allotypic diversity of human ethnic populations
and they do not take into consideration immunodominance.Our new tool Predivac described in this paper implements
a different pan-specific approach based on the concept of
specificity-determining residues (SDRs). This metho-
dology has been previously described by our group for
the prediction of substrate specificity of protein kinases
[18-20]. While the binding interface of a protein can be
extensive, only a small group of SDRs is responsible for
specific interactions. The SDRs have been mainly studied
in peptide recognition domains (e.g., PDZ, SH3 and kinase
domains) of proteins with roles in signalling pathways [21].
Identifying mutations that alter specificity may require a
large amount of experimental work; therefore, a number of
computational approaches have been developed to predict
SDRs. Most of these methods are based on multiple se-
quence alignments and the use of statistical analysis and
evolutionary information to identify SDRs [22]. Other
approaches combine multiple sequence alignments with
structural information of the binding site [23,24] or phy-
sical properties [25]. Like other bioinformatics methods for
CD4+ T-cell epitope prediction, Predivac focuses on pre-
dicting pMHC complex formation. The method assumes
that T cells with the required specificity will be present in
the T-cell repertoire. However, despite improvements in
the performance of methods predicting MHC class II pep-
tide binding, a recent study showed that state-of-the-art
methods are still unsuccessful in predicting CD4+ T-cell
epitopes [26], highlighting the need to develop new
approaches that cope better with epitope discovery. A sig-
nificant source of complexity in EV design comes from the
fact that most of the response is mounted against a few so-
called immunodominant epitopes, despite the presence of
many potential epitopes within an immunogen. This
restricted antigenic specificity of T cells poses a serious
challenge for EV design, as vaccine formulations built on
epitopes that do not dominate the immune response will
not induce effective protection in the vaccinated organism.
Recent evidence suggests that the pMHC kinetic stability
plays a central role in controlling MHC class II peptide
immunogenicity [27]. In concordance with this model, a
strong correlation has been observed between high affinity
HLA class II peptide binding, immunodominance and
promiscuous CD4+ T-cell recognition [28]. Several studies
support this correlation both for MHC class I [29] and
class II proteins [30]. Predivac was consequently developed
using high-affinity binding data, on the assumption that it
is the positive bias toward capturing underlying peptide
features that correlates with promiscuity and immunodo-
minance, two properties that are fundamental for EV de-
sign [31].
In this study, we introduce the pan-specific method
Predivac for CD4+ T-cell epitope prediction, which is
based on the SDR concept previously applied to protein
phosphorylation site prediction. We assessed the per-
formance of Predivac by cross-validation and compared
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art methods in terms of HLA class II peptide binding
and CD4+ T-cell epitope prediction. The comparisons
showed that Predivac performed comparable to ten
competing methods in high-affinity binding prediction,
but delivered the highest specificity in CD4+ T-cell
epitope identification, with a particularly strong per-
formance in immunodominant epitope identification,
compared to three other pan-specific approaches.
Methods
Software implementation
Predivac is written in Perl (v.5.10). Its main component
is a purpose-built database (PredivacDB) constructed
using Berkeley DB. The web implementation available to
the research community is written in Python/CGI. The
server operates on GNU/Linux 2.6 and runs Apache
2.2.16. The software performs three major tasks: i) SDR
identification; ii) binding data retrieval (from PredivacDB
database) and iii) peptide binding prediction.Table 1 HLA class II crystal structures employed to
identify SDRs
Allele Peptide sequence PDB IDs







PKYVKQNTLKLAT 1DLH; 1FYT; 1HXY; 1JWM;
1JWS; 1JWU; 1KG0; 1LO5;















The binding cores of the peptide ligands are highlighted in bold. Underlined
PDB IDs represent the structures that were employed for structural alignment.SDR identification
HLA class II amino acids involved in peptide ligand recog-
nition were identified using a dataset of 37 peptide:HLA
class II complex structures, accounting for 10 different
alleles (DR and DQ loci; Table 1). For each binding po-
sition, residues within a van der Waals radius of 4 Å from
the peptide amino acid were considered as contacting
positions (Pymol, DeLano Scientific). Structural align-
ments of pMHCs were performed with VMD [32]. Se-
quence variability of HLA molecules at the binding
interface was mapped onto the DRB1*0101 allele structure
[PDB:1A6A] using the Protein Variability Server (PVS)
[33]. SDR identification was also aided by a previous
quantum chemistry-based analysis of peptide:HLA class II
interaction [34], where the variation of electrostatic prop-
erties associated with each of the residues involved in pep-
tide binding was assessed and amino acids inducing a
global variation of electrostatic properties in the binding
groove (anchoring amino acids) and those involved in
specific electrostatic variations (recognition amino acids,
responsible for a differential effect) were identified.
PredivacDB database
A key part of the method is PredivacDB, a purpose-built
database of nonameric high-affinity binding peptides and
SDRs. The data in PredivacDB was gathered from three
online repositories (i) The Immune Epitope Data Base
(IEDB) [35]; (ii) MHCBN [36] and (iii) EPIMHC [37].
The collected peptides were additionally filtered by elim-
inating: (i) sequences with length < 9 residues; (ii) non-
natural peptides and sequences having Ala percentage
>50%; (iii) sequences containing a non-natural atom or
group; and (iv) peptides whose binding affinity was
determined only through whole-cell based assays. The
EasyGibbs method [38], based on the Gibbs sampler ap-
proach, was employed to identify nonameric binding
cores, as it is a well-validated tool for motif retrieval in
MHC class II ligands. For each set of peptides, the
retrieved scoring matrix was employed to identify the
binding regions in the peptides. For datasets with small
numbers of peptides, binding motifs were obtained using
the MHC Motif Viewer [39]. PredivacDB was built using
the identified nonameric regions and contains 2695
high-affinity sequences accounting for 29 HLA class II
alleles (Additional file 1: Table S1).
Peptide binding prediction
Predivac predicts peptide binding by establishing a corre-
lation between the SDRs in the HLA query protein and
the SDRs associated with HLA proteins of known specifi-
city. The process involves the following steps: (i) SDRs for
each of the five binding positions are identified in the
query HLA protein sequence; (ii) PredivacDB is queried
and amino acid frequencies and weights are calculated
Oyarzún et al. BMC Bioinformatics 2013, 14:52 Page 4 of 11
http://www.biomedcentral.com/1471-2105/14/52(Equation 1) for peptide sequences associated with allo-
types sharing similar SDRs as the query protein at each
binding position; and (iii) a position-weight matrix
(PWM) is built based on the binding data, consisting of 20
columns (amino acids) × 5 rows (binding sites).
wi;j ¼ log pa;i=pa
  ð1Þ
Where pa,i is the probability of observing amino acid a
at position i of the peptide (i= 0,. . .,8), and pa is the
probability of observing amino acid a in the background
model. The frequency of a residue at position i in the
peptide (fa,i) is estimated using pseudocounts by addingﬃﬃﬃ
n
p





were n is the number of sequences used to calculate the
frequency. SDRs are considered similar if substitution
using the BLOSUM62 matrix gives a positive score.
Finally, T-cell epitope mapping is carried out by pars-
ing query protein sequences into overlapping nonameric
segments (peptides), each of which is assigned a binding
score using the PWM (sliding window technique). Raw
scores are normalized to a 1-100 range using a linear
transformation, considering the minimal and maximal
theoretical peptide scores that can be obtained from the
PWM. A sensible cutoff to discriminate peptides that
bind from those that do not is 60.
Results and discussion
Specificity-determining residues
Structural alignments of the binding groove (α- and β-
domains) were performed with 17 distinct pMHCs out
of 37 structures analyzed (Table 1), accounting for 7 dif-
ferent DR alleles. In cases where a particular complex is
represented by more than one structure, the highest
resolution one was selected. The root-mean-square-dis-
tance of the residues constituting the binding groove
was 0.45 Å, considering Cα atoms of both domains,
reflecting the high level of structural conservation of
residues dictating specificity. This is a condition
required for the SDR method to be applicable. As shown
in Figure 1, the β-domain accounts for the specificity of
the HLA class II proteins, given that 99% of polymorph-
isms are present exclusively in this domain [40]. On the
other hand, there are significantly less polymorphic
positions in alleles belonging to the DP and DQ loci,
and these are distributed both through the α- and β-
domains of the binding groove [40]. The application of
the method for these alleles must be assessed further, as
the specificity seems to be determined by a larger num-
ber of residues than in the case of DR alleles. In
addition, limited binding data is available for HLA DP
and DQ molecules.Fifteen contacting positions on the polymorphic β-
domain were finally considered as SDRs, providing they
exerted an influence on peptide binding, they were struc-
turally conserved, they were polymorphic and they were
identified previously [34] to have an influence on the elec-
trostatic properties of the binding groove (Additional file
1: Figure S1). These key positions allow the relative weight
of the effect of all amino acids on each binding site to be
determined, and predicting whether a peptide is a likely
ligand for a given HLA class II protein. It is worth noting
that, whereas in Predivac the weights are calculated from
binding data (retrieved from PredivacDB), the popular
method TEPITOPE does this using experimentally deter-
mined binding affinities (referred as “pocket profiles”).
Performance assessment and cross-validation
Predivac was assessed both in terms of HLA class II
binding prediction and CD4+ T-cell epitope prediction,
including using a sub-set consisting exclusively of immu-
nodominant epitopes. The accuracy of the predictions
was measured in terms of the area under the ROC curve
(AUC), which represents the probability that the classi-
fier will assign a higher score to a positive example com-
pared to a negative example.
For consistency with previous studies [14,41], Predivac’s
accuracy on HLA class II alleles from PredivacDB was
assessed using a modification of the leave-one-out cross-
validation methodology, whose objective is to minimize
the similarity between the training and test datasets. This
testing procedure, called leave-one-(allele)-out cross-
validation, involves the exclusion of a single allele from
the database and then assessing the performance using
the binding data associated with that particular excluded
allele. Balanced datasets were constructed for AUC calcu-
lation, to have equal number of high-affinity binders (posi-
tives) and non-binders (negatives). The calculation was
repeated ten times using different non-binder datasets
chosen randomly from the ligand source.
For every tested allele, both for peptide binding and
CD4+ T-cell epitope prediction, positive datasets were
constructed using the whole set of epitopes restricted by
it. The negative datasets were constructed by splitting the
protein sequences into overlapping peptides of the same
length as the particular epitope and all peptides except the
annotated peptide were taken as negatives. This is an
established validation strategy, based on the stringent as-
sumption that the misclassification of a few potential pep-
tides (epitopes, representing false negatives) can only lead
to a slight decrease in the overall predictive performance
of the prediction. Redundancy in PredivacDB was
removed by excluding all nonameric peptides equal or
containing any of the sequences present in the CD4+ T-
cell epitope datasets.
Figure 1 HLA class II polymorphism and three-dimensional structure. [PDB:1A6A] is used as a representative structure in this figure.
(A) Ribbon diagram of the binding groove. Chain α, grey; chain β, red. Each chain consists of two domains (α1, α2 and β1, β2, respectively). Only
the ectodomains α1 and β1 shape the binding groove. (B), as (a), but showing the entire molecule. (C) Three-dimensional representation of the
sequence variability in the binding groove, highlighting the location of SDRs in the β1 domain. Variability is represented in a two-colour scale
from blue to red, where blue indicates non-variable positions and red indicates variable positions.
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Predivac implements a method to predict CD4+ T-cell
epitopes that allows coverage of 883 out of 931 HLA
class II DR locus proteins, i.e., 95% of human protein di-
versity. Other pan-specific approaches account for 700
(TEPITOPEpan), 500 (NetMHCIIPan-2.0) and 430 (Multi-
RTA) HLA class II allotypes (according to data reported
in the original publications and web-sites). Additional
file 1: Figure S2 illustrates the performance of Predivac
on the prediction of peptide binding to HLA class II
alleles different from those contained in PredivacDB.
The performance of the method was evaluated for 14
alleles with binding data for at least 25 peptides each.
The average AUC was 0.842. In addition, the perform-
ance of Predivac was tested and compared with nine
state-of-the-art methods implemented as web-servers
using the DFRMLI dataset [42], which has been previ-
ously employed for benchmarking purposes [43]. It
represents the binding affinity distribution in full-length
protein antigens, comprising 103 MHC class II peptides
(15 to 19 residues long) derived from four protein
antigens. The binding data are highly standardized,
accounting for seven HLA-DR molecules (DRB1*0101,
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101,
DRB1*1301 and DRB1*1501). In this study, binding
peptides were defined as those with IC50 ≤ 50 nM. ForDRB1*0701, the threshold was set at 100 nM, while
DRB1*1301 was left out because it does not contain high-
affinity binders. Additional file 1: Table S2 lists the meth-
ods compared. Predivac performed comparably to state-
of-the-art methods. The highest average AUC was delivered
by SMM-align (0.930), with 0.872 for Predivac (Figure 2).
CD4+ T-cell epitope identification
The capability of Predivac to identify CD4+ T-cell epi-
topes was assessed using a dataset gathered from IEDB,
consisting of 1325 of MHC class II-restricted T-cell epi-
topes that account for 43 HLA class II alleles (http://www.
cbs.dtu.dk/suppl/immunology/NetMHCIIpan-2.0/). Only
the pan-specific approaches Predivac, NetMHCIIPan-2.0,
TEPITOPEpan and MultiRTA were considered for per-
formance comparison, as they afford prediction for the
whole set of alleles restricting those epitopes (MHCIIMulti
website was not available). As shown in Figure 3, the result-
ing AUCs were (in decreasing order) 0.749 (Predivac),
0.741 (TEPITOPEpan), 0.728 (NetMHCIIPan-2.0) and
0.710 (MultiRTA). Predivac ROC curve showed a slight
dominance over the high-specificity region (highest true
positive/false positive ratio), which means that the method
delivers the highest performance in identifying immuno-
dominant epitopes correctly. This ability is particularly
relevant given the skewed distribution of the dataset,
Figure 2 Comparison of ten web-accessible methods for HLA class II peptide-binding prediction. Only peptides displaying high-affinity
binding (IC50 ≤ 50 nM) from the DFRMLI dataset were used. Bars indicate the average AUCs.
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tope) and all the remaining peptides are negatives. When
the performance was evaluated for each individual allele
(Additional file 1: Table S3), average AUCs of 0.760 (TEPI-
TOPEpan), 0.759 (NetMHCIIPan-2.0), 0.730 (Predivac)
and 0.725 (MultiRTA) are obtained. These average AUCs
differ slightly from those previously published values using
the same dataset [11], which is a consequence of differences
in the calculation methodology. In our study, AUC values
were calculated using one dataset per allele or per method,
containing simultaneously all positive (epitopes) and nega-
tive examples (as described above), while in the referred
study the AUC values were individually calculated for eachFigure 3 Comparison of overall predictive performance of four
pan-specific methods. Predivac, NetMHCIIPan-2.0, TEPITOPEpan
and MultiRTA were compared in identifying CD4+ T-cell epitopes.protein and subsequently averaged to obtain an allele’s
performance (all protein AUCs associated with each allele)
and a method’s performance (all allele AUCs). Our ap-
proach to calculate unique AUC values over the entire
dataset offers potentially a better representation of the
overall performances. This is further supported by the un-
balance in the dataset, which means that certain alleles
that are considerably underrepresented (e.g., six alleles are
accounted by only one epitope/protein) will have the same
weight as DRB1*0401 (342 examples) if using the averages.
In particular, Predivac’s average is significantly affected by
its poor performance on two alleles, DRB1*1602 and
DRB1*1404, having 3 and 1 epitopes, respectively. Figure 4
shows the predictive performance of Predivac for every
tested allele in relation to the average performance of all
the pan-specific methods. The low standard errors dem-
onstrate a degree of association among the predictive per-
formances over each particular allele, likely reflecting
limitations in the ability of predicting CD4+ T-cell epi-
topes common to all algorithms. The large gap between
the performance of the methods in predicting high-affinity
peptide binding (AUCmax ~0.9) and CD4+ T-cell epitopes
(AUCmax ~0.75) also supports the hypothesis that binding
affinity is not the only factor governing CD4+ T-cell epi-
topes presentation. Abundant evidence points to the influ-
ence of local structural properties of the antigen in the
processing and presentation of the epitopes [44].
An additional benchmarking dataset, based on influenza
virus-specific CD4+ T-cell epitopes from five major influ-
enza virus proteins in mice expressing a distinct set of
class II molecules, was obtained from a recently published
study [26]. For DR1-restricted epitopes (Additional file 1:
Figure S3), both Predivac and NetMHCIIPan-2.0 reached
a comparable accuracy (AUC 0.700), although Predivac
Figure 4 Comparison of the predictive performance of Predivac and the average performance of four pan-specific methods. Predivac
(triangles) and the average performances (circles) of NetMHCIIPan-2.0, TEPITOPEpan and MultiRTA were compared in identifying CD4+ T-cell
epitopes for 43 HLA class II alleles in the dataset. Bars indicate the standard error.
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topes (Additional file 1: Figure S4), Predivac outperformed
the rest of the methods with an AUC of 0.743, followed
by NetMHCIIPan-2.0 (AUC 0.696), TEPITOPEpan
(AUC 0.685) and MultiRTA (AUC 0.641).
High-affinity binding and immunodominance
Available evidence suggests that CD4+ T-cell immuno-
dominance correlates best with the dissociation rate
constant koff [45], and dominant epitopes have been
associated with half-lives (t1/2) ≥ 100 h [46]. A strong
correlation has been established between pMHC class II
high-affinity binding, immunodominance and promiscu-
ity, with half-maximal inhibitory concentration (IC50)
values typically fluctuating around a few nM [47], justify-
ing our affinity threshold of 50 nM for peptide selection
in PredivacDB. We set this threshold in order to drive
the specificity prediction exclusively by high-affinity
binding data and thus potentially favour the identifica-
tion of immunodominant CD4+ T-cell epitopes.
The dissociation rate constant (koff ) plays a crucial
role in ligand-receptor interactions, as it varies over
many orders of magnitude, while the association rate
constant (kon) is often controlled by the rate of diffusion
[48]. This observation is supported by the on-rates for
pMHC class II complexes in the AntiJen database [49]
(Additional file 1: Table S4), and the kinetics of twenty
different peptides binding to the MHC class II protein,
showing diffusion-limited kon values of 10
4-105 M-1s-1
and koff values spanning a range >10
4-fold [50]. A half-
life (t1/2) of 100 h is equivalent to a koff value of 1.925 ×
10-6 s-1 (koff = 0.693/t1/2); thus, the dissociation constant(Kd = koff/ kon) would be between ~0.02 nM (kon = 10
5
M-1s-1) and ~0.2 nM (kon = 10
4 M-1s-1) for the high-
affinity interaction range usually associated with CD4+
T-cell immunodominance.
Immunodominant epitope prediction
Immunodominant and promiscuous epitopes are the best
candidates for EV design; therefore, we benchmarked Pre-
divac in terms of its ability to identify immunodominant
epitopes in full-length proteins. Immunodominance is an
allele-restricted property that in the context of one individ-
ual refers to those epitopes that elicit the largest immune
response. However, because many immunodominant
CD4+ T-cell epitopes have the ability to bind with high-
affinity and to be permissively presented in the context of
multiple DR molecules [51], this study focused on CD4+
T-cell epitopes whose response has been examined in the
context of many individuals expressing diverse haplotypes.
In this case, immunodominant epitopes are those that elicit
the most common response, which may or may not be
immunodominant within the hierarchy of responses of
particular individuals.
A dataset containing 42 immunodominant CD4+ T-
cell epitopes with known allele restriction (12 different
HLA class II alleles) was gathered from the literature
(Additional file 1: Table S5 and Additional file 2), using
a previously published dataset [52] as a basis. The data-
set contains nonameric epitopes known as “universal
epitopes”, as they bind in an apparently indiscriminate
manner to most DR alleles, such as those contained in
the bacterial tetanus toxoid protein (epitope Nº3 in
Additional file 1: Table S5) and in the hemagglutinin
Figure 5 Overall predictive performance of of four pan-specific
methods in identifying immunodominant CD4+ T-cell epitopes.
Overall predictive performance of Predivac, NetMHCIIPan-2.0,
TEPITOPEpan and MultiRTA in identifying immunodominant CD4+ T-
cell epitopes is compared.
Figure 6 Distribution of the percentages corresponding to the
rankings associated with all the CD4+ T-cell immunodominant
epitopes in the context of their corresponding source proteins,
for four pan-specific methods. Predivac, TEPITOPEpan,
NetMHCIIPan-2.0 and MutiRTA are compared. From the bottom up,
the first stack represents the percentage of immunodominant
epitope scores in 0-1% of top scores; second stack: 1-3%; third stack:
3-5%; forth stack: remaining 5-100%.
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gested that these peptides bind the MHC molecule in
the same register but with interactions driving T-cell
recognition variably influenced by the regions flanking
the core [53]. Moreover, longer epitopes are often clus-
ters of dense antigenic regions (hot-spots), such as the
immunodominant epitope spanning residues 378 to 398
of the circumsporozoite protein sequence (epitope
N°36-41), which can bind with several overlapping 9-
mer registers within its 20-mer sequence.
Only minimal immunogenic regions (MHC class II
peptides) with lengths ≤ 13 amino acids were considered
in the dataset, corresponding to the shortest fragment
able to elicit a significant proliferative CD4+ T-cell re-
sponse. DRB1*0101 was kept as a reference allele for all
promiscuous epitopes sharing this restriction. AUC
values were obtained for each allele and for the full data-
set. In addition, for the dataset of immunodominant epi-
topes, the ranking corresponding to the epitope score in
a sorted list of all the scores of same-length peptides in
the source protein was recorded as a percentage (epitope
score ranking/total number of peptides). The ranking
position corresponds to the highest position of a pre-
dicted binding core/epitope (9-mers) where a full-length
match occurs with the actual immunodominant epitope
(9- to 12-mers). For methods hosted at the IEDB website
(SMM-align, TEPITOPE and ARB), which retrieve bind-
ing predictions over 15-mer sequences, only the nona-
meric core associated with the optimal 15-mer sequence
was considered.
Overall, Predivac outperformed other pan-specific
methods, with accuracy slightly higher than NetMHCII-
pan (AUCs 0.918 (Predivac), 0.907 (NetMHCIIPan-2.0),
0.878 (TEPITOPEpan) and 0.840 (MultiRTA)) (Figure 5).
Predivac’s ROC curve for immunodominant CD4+ T-cell
epitopes was superior paticularly over the high-specificity
region (Additional file 1: Figure S5). Fractional AUC
values for the curves over the high-specificity region (spe-
cificity range 0.8-1.0) were 0.145 (Predivac), 0.117
(NetMHCIIPan-2.0), 0.109 (TEPITOPEpan) and 0.104
(MultiRTA). AUC values are within the same range
(around 0.9) as the values obtained for high-affinity
binding prediction (Figure 2), supporting the hypothesis
that the pMHC complex stability is key in dictating
CD4+ T-cell immunodominance, perhaps overpowering
other factors, such as local structural properties, that would
play a role in subdominant epitopes. The average rankings
associated with the immunodominant epitopes in their
source proteins were 2.75 ± 4.39 (Predivac), 5.40 ± 8.09
(NetMHCIIPan-2.0), 8.18 ± 13.30 (MultiRTA) and 8.71 ±
22.10 (TEPITOPEpan). Figure 6 presents the distribution of
these rankings, showing that Predivac outperformed other
approaches by identifying 45% of immunodominant epi-
topes within the top 1%, and 75% of the epitopes within thetop 3% of the scores (the details for each epitope/method
are shown in Additional file 1: Table S6). This result is in
agreement with the high specificity demonstrated by Predi-
vac in the AUC analysis. The second-top performance was
delivered by TEPITOPEpan, in agreement with the fact that
this method is a pan-specific extension of the original high-
quality experimental binding data driving the TEPITOPE
method (pocket profiles). TEPITOPE has been able to
Oyarzún et al. BMC Bioinformatics 2013, 14:52 Page 9 of 11
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endogenous ligands for 1–6% top-scoring peptides [10],
which is consistent with the range for our dataset of ex-
ogenous immunodominant epitopes. It is expected that
TEPITOPEpan inherited these features. Both NetMHCII-
Pan-2.0 and MultiRTA are trained on datasets containing
both high and moderate peptide binders (IC50 ≤ 500 nM),
which could explain to some extent the slightly lower per-
formance on immunodominant epitopes.
It is worth noting that CD4+ T-cell epitope predic-
tions for Predivac, NetMHCIIPan-2.0 and MultiRTA are
likely to present some bias for those alleles present both
in the training datasets and the test sets. Only TEPITO-
PEpan does not depend on experimental binding data.
Even by removing peptide redundancy in PredivacDB, it
is to be expected that the remaining similar peptides
contribute to improving Predivac’s predictive perform-
ance on these alleles. However, the primary objective
of this exercise was benchmarking the pan-specific
approaches under equivalent conditions, therefore; des-
pite this bias the analysis remains informative.
Conclusions
The Predivac method introduced in this paper imple-
ments a pan-specific approach for HLA class II binding
predictions based on the SDR concept. It displays a
wider coverage yet performs comparable to other avail-
able methods. For CD4+ T-cell epitope prediction, Pre-
divac delivered the highest specificity, which is valuable
in epitope discovery, given the need to correctly identify
a few CD4+ T-cell epitopes among a large number of
non-epitopes. Furthermore, an association with individ-
ual allotypes was observed among the AUC values for all
methods, which possibly highlights a barrier imposed by
biological variables not accounted for by the models. All
methods performed better when they were assessed on
immunodominant CD4+ T-cell epitopes, reaching simi-
lar accuracy levels to those obtained for high-affinity
peptide-binding prediction. For the immunodominant
CD4+ T-cell epitope dataset, Predivac outperformed
competing methods (AUC 0.918), particularly standing
out in terms of its high specificity, which allowed identi-
fication of 75% of immunodominant epitopes within the
top 3% scoring peptides. This outcome supports our the-
sis that driving the prediction with high-affinity binding
data can impose an advantageous bias toward capturing
underlying peptide features that correlate with stable
peptide-MHC binding, and subsequently increases the
probability of identifying immunodominant CD4+ T-cell
epitopes.
Predivac users need to be aware of the limitations
imposed by the approach Predivac is based on. The
method assumes that interactions between the protein
and the peptide are independent for each peptideposition, and the prediction of CD4+ T-cell epitopes fo-
cuses solely on peptide binding to the MHC molecule as
the most discriminative determinant of immune re-
sponse. These limitations will be addressed in future
work.
Predivac provides CD4+ T-cell epitope predictions over
95% of HLA class II DR allotypes, making it a valuable
tool to aid EV design in the context of an ethnically het-
erogeneous population. Ultimately, by enabling highly spe-
cific immunodominant epitope identification, we expect
our tool to be helpful in the vaccination strategy of target-
ing simultaneously multiple dominant and subdominant
epitopes from one or several pathogen proteins, overcom-
ing the propensity of the immune system to focus on a
very limited set of epitopes. We are currently extending
the tool to better facilitate EV design by considering allele
frequency data and population coverage.Additional files
Additional file 1: Supplementary tables and figures. This pdf file
contains Tables S1-S6 and Figures S1-S5.
Additional file 2: Immunodominant epitope dataset. This text file
contains the immunodominant CD4+ T-cell epitope dataset, including
their associated allele restrictions and source protein sequences. This
dataset was employed to assess the performance of Predivac,
NetMHCIIpan, TEPITOPEpan and MultiRTA in identification of these
epitopes.
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